What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

Autor: Kamila Castro Grokoski, Christina G S Fraga, Guilherme Bosi, Liane Esteves Daudt, M. P. Pereira, Lucia Mariano da Rocha Silla, Tito Vanelli Costa, Marco Antônio Baptista Kalil, Nathan Bugs, Laura Fogliatto

Publikováno v: Hematology, Transfusion and Cell Therapy
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 3, Pp 222-228 (2019)

Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b517f49a0261d6e051c23305e04d8716
https://pubmed.ncbi.nlm.nih.gov/31085148

BCR-ABL Fluctuation in Chronic Myeloid Leukemia (CML) Patients with Deep Molecular Response (MR): What is the Meaning of a Big Wave when You Test the Patients in Different Laboratories?

Autor: Marco Abkalil, Andrea Kramer, Lucia Mariano da Rocha Silla, Mariana Pinto, Guilherme Bosi, Kamila Castro Grokoski, Tito Vanelli Costa, Laura Fogliatto

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 17:S316-S317

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c43841d6a8ba213600df09e892608c15
https://doi.org/10.1016/j.clml.2017.07.118

The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Autor: Tânia Hellwig, Mariza Shaan, Tito Vanelli Costa, Juarez Fontoura Silveira, Raquel Breunig, Adriana Zardo, Mayde Seadi Torriani, Denise Almeida, Lucia Mariano da Rocha Silla, Luis Carlos Zanandrea Contin, Mario Sérgio Fernandes, Moema Nene, Tahiane de Brum Soares, Tiago Daltoe, Marco Antônio Schilling, Mariangela Moschen, Joao Ricardo Friedrisch, Marcelo Capra, Laura Fogliatto, Liane Esteves Daudt, Katia Fassina

Publikováno v: Blood. 124:5536-5536

Background Monitoring response to TKI therapy is one of the key management strategies of chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is emerging as an effective prognostic factor indicator of long-term durable r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f2eef8321ee0d6ded820e58c77e4216
https://doi.org/10.1182/blood.v124.21.5536.5536

The Assessment of the European Leukemianet Criteria for Clinicohematologic Resistance and Intolerance to Hydroxyurea in Polycythemia Vera Is Not Easily Applicable in Daily Practice

Autor: Tito Vanelli Costa, Liane Esteves Daudt, Laura Fogliatto, Raquel Breunig, Luis Carlos Zanandrea Contin, Cinara Silveira, Lucia Mariano da Rocha Silla, Juarez Fontoura Silveira

Publikováno v: Blood. 124:5550-5550

Background Polycythemia vera (PV) is a subgroup of myeloproliferative neoplasm (MPN) BCL-ABL1 negative. The current therapy of PV should be aimed at preventing vascular complications and avoid increasing the risk of leukemic transformation. The thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d508204fe2f2050263236126dafa8e3a
https://doi.org/10.1182/blood.v124.21.5550.5550

The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities

Autor: Saozan Ahmad, Sabrina Wisintainer, Viviane Magagnin Fernandes, Mariangela Moschen, Moema Nene, Mariza Shaan, Mario Sérgio Fernandes, Tito Vanelli Costa, Tiago Daltoe, Laura Fogliatto, Marco Antônio Schilling, Juliana Kratochvil, Cheila Eickhoff, Andréia Dias Almeida, Tânia Hellwig, Marcelo Capra, Adriana Zardo, Virginia Maria Coser, Márcia Leite, Lucia Mariano da Rocha Silla, Dayane Bohn Koshiyama, Denise Almeida, Waldir Veiga Pereira, Katia Fassina, Liane Esteves Daudt, Nathália Guterres Xavier, Dalnei Veiga Pereira, Vitor Lenz, Mayde Seadi Torriani

Publikováno v: Blood. 118:4423-4423

Abstract 4423 Background Treatment of chronic myeloid leukemia with imatinib leads to disease remission in a majority of patient, but in some patients (pts) controlling the disease remains a challenge. One of the proposed prognostic factors for ident

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c7e7b2ed6e88ea21230d2eb7938cc2f
https://doi.org/10.1182/blood.v118.21.4423.4423